Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients

Eur J Cancer. 2006 Oct;42(15):2660-1. doi: 10.1016/j.ejca.2006.06.009. Epub 2006 Aug 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / genetics
  • Drug Administration Schedule
  • Humans
  • Middle Aged
  • Neoplasm Proteins / metabolism
  • Receptor, ErbB-2 / metabolism
  • Trastuzumab
  • Treatment Outcome
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / genetics

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Neoplasm Proteins
  • Receptor, ErbB-2
  • Trastuzumab